Thrombophilia and Pregnancy

M.V. Galaiko, O.V. Rybina, M.S. Litvinenko, Yu.V. Klimov, B.Yu. Al’tshuler, Andrei Vladimirovich Gubkin,

DOI:

https://doi.org/10.21320/2500-2139-2017-10-3-409-422

Background. Women with a predisposition to thrombosis (thrombophilia) during pregnancy develop pathological hypercoagulation, which can lead to early and late pregnancy losses. The most significant polymorphisms of thrombophilia genes include antithrombin III deficiency, protein C deficiency, Leiden mutation, hereditary hyperhomocysteinemia, and mutations of other clotting factors. In addition, several forms of thrombophilia are caused by hyperaggregation. Currently, heparin and its derivatives are considered the safest and most effective agents for the prevention and therapy of thrombosis. However, it is impossible to evaluate the efficacy of heparins using only standard methods (activated partial thromboplastin time, thrombin time, prothrombin time) and markers of intravascular coagulation activation (soluble fibrin-monomer complexes, D-dimer) due to their insufficient sensitivity. One of the new tests of qualitative and quantitative evaluation of the plasma coagulation system is thrombodynamics test, which allows to detect even minimal coagulation disturbances.

Aim. The aim was to evaluate the use of the thrombodynamics test in women with first trimester pregnancy pathology. The authors aimed to show the high sensitivity of this test for the monitoring of treatment with low molecular weight heparins (LMWH).

Methods. The study included 23 pregnant women with pregnancy pathology and/or history of thrombosis and threatening miscarriage in the first trimester. The women were aged 22–38 years (median age 30 years). The complex evaluation of the hemostatic system was performed using the thrombodynamics test.

Results. LMWH therapy with the thrombodynamics monitoring was administered to 20 of 23 women. The statistically significant changes were observed only for thrombodynamics indices (p < 0.05). The total of 14 women delivered healthy children at 38–40 weeks (all patients received LMWH in the first trimester).

Conclusion. The thrombodynamics test was the most reliable method of monitoring LMWH therapy, since it allows recording even minimal coagulation disturbances.

  • M.V. Galaiko NA Semashko Central Clinical Hospital No. 2, 2 Budaiskaya str., Moscow, Russian Federation, 129128 ; Центральная клиническая больница № 2 им. Н.А. Семашко ОАО «РЖД», ул. Будайская, д. 2, Москва, Российская Федерация, 129128
  • O.V. Rybina NA Semashko Central Clinical Hospital No. 2, 2 Budaiskaya str., Moscow, Russian Federation, 129128 ; Центральная клиническая больница № 2 им. Н.А. Семашко ОАО «РЖД», ул. Будайская, д. 2, Москва, Российская Федерация, 129128
  • M.S. Litvinenko NA Semashko Central Clinical Hospital No. 2, 2 Budaiskaya str., Moscow, Russian Federation, 129128 ; Центральная клиническая больница № 2 им. Н.А. Семашко ОАО «РЖД», ул. Будайская, д. 2, Москва, Российская Федерация, 129128
  • Yu.V. Klimov NA Semashko Central Clinical Hospital No. 2, 2 Budaiskaya str., Moscow, Russian Federation, 129128 ; Центральная клиническая больница № 2 им. Н.А. Семашко ОАО «РЖД», ул. Будайская, д. 2, Москва, Российская Федерация, 129128
  • B.Yu. Al’tshuler NA Semashko Central Clinical Hospital No. 2, 2 Budaiskaya str., Moscow, Russian Federation, 129128 ; Центральная клиническая больница № 2 им. Н.А. Семашко ОАО «РЖД», ул. Будайская, д. 2, Москва, Российская Федерация, 129128
  • Andrei Vladimirovich Gubkin NA Semashko Central Clinical Hospital No. 2, 2 Budaiskaya str., Moscow, Russian Federation, 129128 ; Центральная клиническая больница № 2 им. Н.А. Семашко ОАО «РЖД», ул. Будайская, д. 2, Москва, Российская Федерация, 129128
  1. Lipets EN, Ataullakhanov FI. Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis Risk. Thrombosis J. 2015;13(1):4. doi: 10.1186/s12959-015-0038-0. DOI: https://doi.org/10.1186/s12959-015-0038-0
  2. Hellgren M. Hemostasis during normal pregnancy and puerperium. Sem Thromb Hemost. 2003;29(2):125–30. doi: 10.1055/s-2003-38897. DOI: https://doi.org/10.1055/s-2003-38897
  3. Козлов А.А., Натрус Л.В., Черновол П.А. и др. Лабораторная диагностика системы гемостаза. М.: Литтерра, 2011. 136 с.
  4. [Kozlov AA, Natrus LV, Chernovol PA, et al. Laboratornaya diagnostika sistemy gemostaza. (Laboratory diagnostics of hemostasis system.) Moscow: Litterra Publ.; 2011. 136 p. (In Russ)]
  5. Heit JA. Thrombophilia: Common Questions on Laboratory Assessment and Management Hematology. Hematology. 2007(1):127–35. doi: 10.1182/asheducation-2007.1.127. DOI: https://doi.org/10.1182/asheducation-2007.1.127
  6. Armstrong EM, Bellone JM, Hornsby LB, et al. Acquired Thrombophilia. J Pharm Pract. 2014;27(3):234–42. doi: 10.1177/0897190014530424. DOI: https://doi.org/10.1177/0897190014530424
  7. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complication of pregnancy. N Engl J Med. 1999;340(1):9–13. doi: 10.1056/NEJM199901073400102. DOI: https://doi.org/10.1056/NEJM199901073400102
  8. Khalafallah AA, Ibraheem AR, Teo QY, et al. Review of management and outcomes in women with thrombophilia risk during pregnancy at a single institution. Obstet Gynecol. 2014;2014:1–6. doi: 10.1155/2014/381826. DOI: https://doi.org/10.1155/2014/381826
  9. Patel EM, Goodnight WH, James AH, Grotegut CA. Temporal trends in maternal medical conditions and stillbirth. Am J Obstet Gynecol. 2015;212(5):673, e1–11. doi: 10.1016/j.ajog.2014.12.021. DOI: https://doi.org/10.1016/j.ajog.2014.12.021
  10. Coriu L, Copaciu E, Tulbure D, et al. Inherited thrombophilia in pregnant women with intrauterine growth restriction. J Clin Med. 2014;9(4):351–5. doi: 10.1016/j.ijgo.2007.04.025. DOI: https://doi.org/10.1016/j.ijgo.2007.04.025
  11. Бицадзе В.О., Макацария А.Д., Хизроева Д.Х. и др. Тромбофилия как важнейшее звено патогенеза осложнений беременности. Практическая медицина. 2012;5(60):22–9.
  12. [Bitsadze VO, Makatsariya AD, Khizroeva DKh, et al. Thrombophilia as the most important link in the pathogenesis of pregnancy complications. Prakticheskaya meditsina. 2012;5(60):22–9. (In Russ)]
  13. Александрова Н.В., Баев О.Р. Ранние этапы становления системы мать-плацента-плод. Акушерство и гинекология. 2011;8:4–10.
  14. [Aleksandrova NV, Baev OR. Stages of formation of the mother-placenta-fetus system. Akusherstvo i ginekologiya. 2011;8:4–10. (In Russ)]
  15. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109(8):3161–72. doi: 10.1182/blood-2006-09-003004. DOI: https://doi.org/10.1182/blood-2006-09-003004
  16. Asahina T, Kobayashia T, Okada Y, et al. Maternal Blood Coagulation Factor XIII is Associated with the Development of Cytotrophoblastic Shell. Placenta. 2000;21(4):388–93. doi: 10.1053/plac.1999.0489. DOI: https://doi.org/10.1053/plac.1999.0489
  17. Many A, Schreiber L, Rosner S, et al. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol. 2001;98(6):1041–4. doi: 10.1097/00006250-200112000-00010. DOI: https://doi.org/10.1097/00006250-200112000-00010
  18. Khan S, Dickerman JD. Hereditary thrombophilia. Thrombosis J. 2006;4(1):15. doi: 10.1186/1477-9560-4-15. DOI: https://doi.org/10.1186/1477-9560-4-15
  19. Sanson BJ, Friederich PW, Simioni P, et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost. 1996;75(3):387–8. DOI: https://doi.org/10.1055/s-0038-1650282
  20. Lenz B, Samardzija M, Drenjancevic D, et al. The investigation of hereditary and acquired thrombophilia risk factors in the development of complications in pregnancy in Croatian women. J Mat-Fet Neonat Med. 2016;29(2):264–9. doi: 10.3109/14767058.2014.998189. DOI: https://doi.org/10.3109/14767058.2014.998189
  21. Mannuccio PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost. 2015;114(5):885–9. doi: 10.1160/TH15-02-0141. DOI: https://doi.org/10.1160/TH15-02-0141
  22. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. Thromb Haemost. 2009;7(Suppl 1):301–4. doi: 10.1111/j.1538-7836.2009.03394.x. DOI: https://doi.org/10.1111/j.1538-7836.2009.03394.x
  23. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64–7. doi: 10.1038/369064a0. DOI: https://doi.org/10.1038/369064a0
  24. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3ʹ-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698–703. DOI: https://doi.org/10.1182/blood.V88.10.3698.bloodjournal88103698
  25. Kocher O, Cirovic C, Malynn E, et al. Obstetric Complications in Patients With Hereditary Thrombophilia Identified Using the LCx Microparticle Enzyme Immunoassay: a controlled study of 5,000 patients. Am J Clin Pathol. 2007;127(1):68–75. doi: 10.1309/JWL27GRGU71VP5QL. DOI: https://doi.org/10.1309/J64R-8020-2J71-2K80
  26. Sergi C, Jishi TA, Walker M. Factor V Leiden mutation in women with early recurrent pregnancy loss: a meta-analysis and systemic review of the causal association. Arch Gynecol Obstet. 2015;291(3):671–9. doi: 10.1007/s00404-014-3443-x. DOI: https://doi.org/10.1007/s00404-014-3443-x
  27. Gao H, Tao FB. Prothrombin G20210A mutation is associated with recurrent pregnancy loss: A systemic review and meta-analysis update. Thromb Res. 2014;135(2):339–46. doi: 10.1016/j.thromres.2014.12.001. DOI: https://doi.org/10.1016/j.thromres.2014.12.001
  28. Mierla D, Szmal C, Neagos D, et al. Association of Prothrombin (G20210A) and Factor V Leiden (A506G) with Recurrent Pregnancy Loss. Maedica (Buchar). 2012;7(3):222–6.
  29. Калашникова Е.А., Кокаровцева С.Н. Ассоциация наследственных факторов тромбофилии с невынашиванием беременности у женщин в русской популяции. Медицинская генетика. 2005;4(8):386–90.
  30. [Kalashnikova EA, Kokarovtseva SN. Association between congenital thrombophilia and fetal loss in the Russian population. Meditsinskaya genetika. 2005;4(8):386–90. (In Russ)]
  31. Kim SY, Park SY, Choi JW, et al. Association Between MTHFR 1298A>C Polymorphism and Spontaneous Abortion with Fetal Chromosomal Aneuploidy. Am J Reprod Immunol. 2011;66(4):252–8. doi: 10.1111/j.1600-0897.2011.00996.x. DOI: https://doi.org/10.1111/j.1600-0897.2011.00996.x
  32. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111–3. doi: 10.1038/ng0595-111. DOI: https://doi.org/10.1038/ng0595-111
  33. Sharma GS, Kumar T, Dar TA, Singh LR. Protein N-homocysteinylation: From cellular toxicity to neurodegeneration. Biochim Biophys Acta. 2015;1850(11):2239–45. doi: 10.1016/j.bbagen.2015.08.013. DOI: https://doi.org/10.1016/j.bbagen.2015.08.013
  34. Jakubowski H. Pathophysiological Consequences of Homocysteine Excess. J Nutr. 2006;136(6 Suppl):1741S–49S. DOI: https://doi.org/10.1093/jn/136.6.1741S
  35. Спиридонова М.Г., Трифонова Е.А., Фадюшина С.В. и др. Молекулярно-генетический анализ полиморфных маркеров генов, ответственных за функционирование факторов эндотелиальной системы в связи с осложненным протеканием беременности. Сибирский медицинский журнал. 2007;6(7):38–42.
  36. [Spiridonova MG, Trifonova EA, Fadyushina SV, et al. Molecular-genetics analysis of the polymorphic markers of the genes involved in endothelial system function in connection with abnormal pregnancy. Sibirskii meditsinskii zhurnal. 2007;6(7):38–42. (In Russ)]
  37. Farahmand K, Totonchi M, Hashemi M, et al. Thrombophilic genes alterations as risk factor for recurrent pregnancy loss. J Mat-Fet Neonat Med. 2015;29(8):1269–73. doi: 10.3109/14767058.2015.1044431. DOI: https://doi.org/10.3109/14767058.2015.1044431
  38. Larciprete G, Rossi F, Deaibess T, et al. Double inherited thrombophilias and adverse pregnancy outcomes: Fashion or science? J Obstet Gynaecol Res. 2010;36(5):996–1002. doi: 10.1111/j.1447-0756.2010.01262.x. DOI: https://doi.org/10.1111/j.1447-0756.2010.01262.x
  39. Booth NA, Reith A, Bennett B. A plasminogen activator inhibitor (PAI-2) circulates in two molecular forms during pregnancy. Thromb Haemost. 1988;59(1):77–9. DOI: https://doi.org/10.1055/s-0038-1642569
  40. Долгов В.В., Свирин П.В. Лабораторная диагностика нарушений гемостаза. М., Тверь: Триада, 2005. С. 64.
  41. [Dolgov VV, Svirin PV. Laboratornaya diagnostika narushenii gemostaza. (Laboratory diagnosis of hemostasis disorders.) Moscow, Tver’: Triada Publ.; 2005. pp. 64. (In Russ)]
  42. Kruithof EK, Tran-Thang C, Gudinchet A, et al. Fibrinolysis in Pregnancy: A Study of Plasminogen Activator. Blood. 1987;69(2):460–6. DOI: https://doi.org/10.1182/blood.V69.2.460.460
  43. Humphries SE, Panahloo A, Montgomery HE, et al. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb Haemost. 1997;78(1):457–61. DOI: https://doi.org/10.1055/s-0038-1657569
  44. Humphries SE, Lane A, Dawson S, Green FR. The study of gene-environment interactions that influence thrombosis and fibrinolysis. Genetic variation at the loci for factor VII and plasminogen activator inhibitor-1. Arch Pathol Lab Med. 1992;116(12):1322–9.
  45. Li X, Liu Y, Zhang R, et al. Meta-Analysis of the Association between Plasminogen Activator Inhibitor-1 4G/5G Polymorphism and Recurrent Pregnancy Loss. Med Sci Monit. 2015;21:1051–6. doi: 10.12659/MSM.892898. DOI: https://doi.org/10.12659/MSM.892898
  46. Chen H, Nie S, Lu M. Association between Plasminogen Activator Inhibitor-1 Gene Polymorphisms and Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis. Am J Reprod Immunol. 2015;73(4):292–300. doi: 10.1111/aji.12321. DOI: https://doi.org/10.1111/aji.12321
  47. Баркаган З.С., Момот А.П. Диагностика и контролируемая терапия нарушений системы гемостаза. М.: Ньюдиамед, 2001. 292 с.
  48. [Barkagan ZS, Momot AP. Diagnostika i kontroliruemaya terapiya narushenii sistemy gemostaza. (Diagnosis and targeted therapy of hemostasis disorders.) Moscow: N’yudiamed Publ.; 2001. 292 p. (In Russ)]
  49. Bussel JB, Kunicki TJ, Michelson AD. Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease. Hematology. 2000;2000(1):222–40. doi: 10.1182/asheducation-2000.1.222. DOI: https://doi.org/10.1182/asheducation.V2000.1.222.222
  50. Гусина А.А. Генетический полиморфизм гликопротеиновых рецепторов тромбоцитов как фактор риска тромбообразования. Кардиология в Беларуси. 2009;3:17–24.
  51. [Gusina AA. Genetic polymorphism of platelet glycoprotein receptors as a risk factor for thrombosis. Kardiologiya v Belarusi. 2009;3:17–24. (In Russ)]
  52. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/ proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Investig. 1989;83(5):1778–81. doi: 10.1172/JCI114082. DOI: https://doi.org/10.1172/JCI114082
  53. O’Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation. Circulation. 2001;103(25):3051–6. DOI: https://doi.org/10.1161/01.CIR.103.25.3051
  54. Santoro SA, Zutter MM. The alpha 2 beta 1 integrin: a collagen receptor on platelets and other cells. Thromb Haemost. 1995;74(3):813–21. DOI: https://doi.org/10.1055/s-0038-1649829
  55. Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin alpha 2 beta 1 activity on human platelets. Blood. 1993;82(9):2693–703. DOI: https://doi.org/10.1182/blood.V82.9.2693.bloodjournal8292693
  56. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood. 1997;89(6):1939–43. DOI: https://doi.org/10.1182/blood.V89.6.1939
  57. Ruzzi L, Ciarafoni I, Silvestri L, et al. Association of PLA2 polymorphism of the ITGB3 gene with early fetal loss. Fertil Steril. 2005;83(2):511–2. doi: 10.1016/j.fertnstert.2004.10.024. DOI: https://doi.org/10.1016/j.fertnstert.2004.10.024
  58. Hunt LT, Dayhoff MO. A surprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha 1-proteinase inhibitor. Biochem Biophys Res Commun. 1980;95(2):864–71. DOI: https://doi.org/10.1016/0006-291X(80)90867-0
  59. Maclean PS, Tait RC. Hereditary and Acquired Antithrombin Deficiency Epidemiology, Pathogenesis and Treatment Options. Drugs. 2007;67(10):1429–40. DOI: https://doi.org/10.2165/00003495-200767100-00005
  60. Lane DA, Olds RJ, Thein SL. Antithrombin III: summary of first database update. Nucl Acids Res. 1994;22(17):3556–9.
  61. Ilonczai P, Olah Z, Selmeczi A, et al. Management and outcome of pregnancies in women with antithrombin deficiency: a single-center experience and review of literature. Blood Coagul Fibrinol. 2015;26(7):798–804. doi: 10.1097/MBC.0000000000000348. DOI: https://doi.org/10.1097/MBC.0000000000000348
  62. Bramham K, Retter A, Robinson SE, et al. How I treat heterozygous hereditary antithrombin deficiency in pregnancy. Thromb Haemost. 2013;110(3):550–9. doi: 10.1160/TH13-01-0077. DOI: https://doi.org/10.1160/TH13-01-0077
  63. Buchanan GS, Rodgers GM, Branch WD. The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation. Best Pract Res Clin Obstet Gynaecol. 2003;17(3):397–411. DOI: https://doi.org/10.1016/S1521-6934(03)00010-5
  64. Comp PC, Thurnau GR, Welsh J, Esmon CT. Thurnau Functional and Immunologic Protein S Levels Are Decreased During Pregnancy. Blood. 1986;68(4):881–5. DOI: https://doi.org/10.1182/blood.V68.4.881.bloodjournal684881
  65. Basaran A, Deren O, Buyukasik Y, Basaran M. Free Protein S Reference Ranges in Gravidas Without Hereditary and Acquired Thrombophilia. Indian J Hematol Blood Tranfus. 2015;31(2):286–91. doi: 10.1007/s12288-014-0448-3. DOI: https://doi.org/10.1007/s12288-014-0448-3
  66. Brenner B. Haemostatic changes in pregnancy. Thromb Res. 2004;114(5–6):409–14. doi: 10.1016/j.thromres.2004.08.004. DOI: https://doi.org/10.1016/j.thromres.2004.08.004
  67. Gris JC, Quere I, Monpeyroux F, et al. Case-control Study of the Frequency of Thrombophilic Disorders in Couples with Late Fetal Loss and no Thrombotic Antecedent The Nimes Obstetricians and Haematologists Study 5 (NOHA 5). Thromb Haemost. 1999;81(6):891–9. DOI: https://doi.org/10.1055/s-0037-1614594
  68. Ebina Y, Ieko M, Naito S, et al. Low levels of plasma protein S, protein C and coagulation factor XII during early pregnancy and adverse pregnancy outcome. Thromb Haemost. 2015;114(1):65–9. doi: 10.1160/TH14-11-0928. DOI: https://doi.org/10.1160/TH14-11-0928
  69. Каде А.Х., Занин С.А., Губарева Е.А. и др. Физиологические функции сосудистого эндотелия. Фундаментальные исследования. 2011;11(3):611–7.
  70. [Kade AKh, Zanin SA, Gubareva EA, et al. Physiological functions of the endothelium. Fundamental’nye issledovaniya. 2011;11(3):611–7. (In Russ)]
  71. Faught W, Garner P, Jones G, Ivey B. Changes in protein C and protein S levels in normal pregnancy. Am J Obstet Gynecol. 1995;172(1 Pt 1):147–50. DOI: https://doi.org/10.1016/0002-9378(95)90104-3
  72. Marlar RA, Mastovich S. Hereditary protein C deficiency: a review of the genetics, clinical presentation, diagnosis and treatment. Blood Coagul Fibrinol. 1990;1(3):319–30. DOI: https://doi.org/10.1097/00001721-199008000-00010
  73. Goldenberg NA, Manco-Johnson MJ. Protein C deficiency. Haemophilia. 2008;14(6):1214–21. doi: 10.1111/j.1365-2516.2008.01838.x. DOI: https://doi.org/10.1111/j.1365-2516.2008.01838.x
  74. Folkeringa N, Brouwer JL, Korteweg FJ, et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Hematol. 2007;136(4):656–61. doi: 10.1111/j.1365-2141.2006.06480.x. DOI: https://doi.org/10.1111/j.1365-2141.2006.06480.x
  75. Mosesson MW. Dysfibrinogenemia and thrombosis. Thromb Haemost. 1999;25(3):311–9. doi: 10.1055/s-2007–994933. DOI: https://doi.org/10.1055/s-2007-994933
  76. Стуров В.Г., Чупрова А.В., Антонов А.Р., Анмут С.Я. Наследственные дисфибриногенемии: современное состояние проблемы клинико-лабораторной диагностики и направленной терапии. Гематология и трансфузиология. 2005;5:35–40.
  77. [Sturov VG, Chuprova AV, Antonov AR, Anmut SYa. Genetic dysfibrinogenemias: current problems of diagnosis and targeted treatment. Gematologiya i transfuziologiya. 2005;5:35–40. (In Russ)]
  78. Li JF, Lin Y, Yang YH, et al. Fibrinogen Aα Thr312Ala Polymorphism Specifically Contributes to Chronic Thromboembolic Pulmonary Hypertension by Increasing Fibrin Resistance. PloS One. 2013;8(7):e69635. doi: 10.1371/journal.pone.0069635. DOI: https://doi.org/10.1371/journal.pone.0069635
  79. Kamimoto Y, Wada H, Ikejiri M, et al. Hypofibrinogenemia and the α-Fibrinogen Thr312Ala Polymorphism may be Risk Factors for Early Pregnancy Loss. Clin Appl Thromb Hemost. 2017;23(1):52–7. doi: 10.1177/1076029615594003. DOI: https://doi.org/10.1177/1076029615594003
  80. Szecsi PB, Jorgensen M, Klajnbard A, et al. Haemostatic reference intervals in pregnancy. Thromb Haemost. 2010;103(4):718–27. doi: 10.1160/TH09-10-0704. DOI: https://doi.org/10.1160/TH09-10-0704
  81. Долгов В.В., Свирин П.В. Лабораторная диагностика нарушений гемостаза. М., Тверь: Триада, 2005. 227 с.
  82. [Dolgov VV, Svirin PV. Laboratornaya diagnostika narushenii gemostaza. (Laboratory diagnosis of hemostasis disorders.) Moscow, Tver’: Triada Publ.; 2005. 227 p. (In Russ)]
  83. Ponczek MB, Gailani D, Doolittle RF. Evolution of the contact phase of vertebrate blood coagulation. J Thromb Haemost. 2008;6(11):1876–83. doi: 10.1111/j.1538-7836.2008.03143.x. DOI: https://doi.org/10.1111/j.1538-7836.2008.03143.x
  84. Konings J, Hoving LR, Ariens RS, et al. The role of activated coagulation factor XII in overall clot stability and fibrinolysis. Thromb Res. 2015;136(2):474–80. doi: 10.1016/j.thromres.2015.06.028. DOI: https://doi.org/10.1016/j.thromres.2015.06.028
  85. Xu-Cai YO, Shen J, Chen S, et al. Factor XII Gene Mutation in the Hageman Family. J Thromb Haemost. 2011;9(11):2329–31. doi: 10.1111/j.1538-7836.2011.04508.x. DOI: https://doi.org/10.1111/j.1538-7836.2011.04508.x
  86. Момот А.П., Кудинова И.Ю., Батрак Т.A. Фибринолитическая активность крови при физиологически протекающей беременности — от прегравиного периода до родов. Репродуктивная медицина (Казахстан). 2014;3–4(20–21):41.
  87. [Momot AP, Kudinova IYu, Batrak TA. Fibrinolysis in normal pregnancy: from preconception to delivery. Reproduktivnaya meditsina (Kazakhstan). 2014;3–4(20–21):41. (In Russ)]
  88. D’Uva M, Strina I, Mollo A, et al. Acquired factor XII deficiency in a woman with recurrent pregnancy loss: working on a differential diagnosis in a single case. J Transl Med. 2005;3(1):43. doi: 10.1186/1479-5876-3-43. DOI: https://doi.org/10.1186/1479-5876-3-43
  89. Asano E, Ebara T, Yamada-Namikawa C, et al. Genotyping Analysis for the 46 C/T Polymorphism of Coagulation Factor XII and the Involvement of Factor XII Activity in Patients with Recurrent Pregnancy. PloS One. 2014;9(12):e114452. doi: 10.1371/journal.pone.0114452. DOI: https://doi.org/10.1371/journal.pone.0114452
  90. Jones DW, Gallimore MJ, Mackie IJ, et al. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol. 2000;110(3):721–6. doi: 10.1046/j.1365-2141.2000.02251.x. DOI: https://doi.org/10.1046/j.1365-2141.2000.02251.x
  91. Ozgu-Erdinc AS, Togrul C, Aktulay A, et al. Factor XII (Hageman) Levels in Women with Recurrent Pregnancy Loss. J Pregn. 2014;2014:1–3. doi: 10.1155/2014/459192. DOI: https://doi.org/10.1155/2014/459192
  92. Мамаев А.Н. Практическая гемостазиология. М.: Практическая медицина, 2014. 148 с.
  93. [Mamaev AN. Prakticheskaya gemostaziologiya. (Practical hemostasiology.) Moscow: Prakticheskaya meditsina Publ.; 2014. 148 p. (In Russ)]
  94. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII Deficiency. Sem Thromb Hemost. 2009;35(4):426–38. doi: 10.1055/s-0029-1225765. DOI: https://doi.org/10.1055/s-0029-1225765
  95. Ariens RA, Philippou H, Nagaswami C, et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000;96(3):988–95. DOI: https://doi.org/10.1182/blood.V96.3.988.015k57_988_995
  96. Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M, et al. Plasminogen Activator Inhibitor 1 4G/5G Polymorphism and Coagulation Factor XIII Val34Leu Polymorphism: Impaired Fibrinolysis and Early Pregnancy Loss. Clin Chem. 2003;49(7):1081–6. DOI: https://doi.org/10.1373/49.7.1081
  97. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systemic review. Eur J Obstet Gynecol. 2002;101(1):6–14. DOI: https://doi.org/10.1016/S0301-2115(01)00496-1
  98. Макацария А.Д., Бицадзе В.О., Хизроева Д.Х. и др. Применение низкомолекулярного гепарина при тромбофилических состояниях в акушерской практике. Российский медицинский журнал. 2005;17:1130.
  99. [Makatsariya AD, Bitsadze VO, Khizroeva DKh, et al. The use of low molecular weight heparin for thrombophilia disorders in obstetrics. Rossiiskii meditsinskii zhurnal. 2005;17:1130. (In Russ)]
  100. Ginsberg JS, Hirsh J. Anticoagulants During pregnancy. Ann Rev Med. 1989;40:79–86. doi: 10.1146/annurev.me.40.020189.000455. DOI: https://doi.org/10.1146/annurev.me.40.020189.000455
  101. Stevenson RE, Burton OM, Ferlauto GJ, et al. Hazard of oral anticoagulants during pregnancy. JAMA Netw. 1980;243(15):1549–51. doi: 10.1001/jama.1980.03300410037022. DOI: https://doi.org/10.1001/jama.1980.03300410037022
  102. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):627S–44S. doi: 10.1378/chest.126.3_suppl.627S. DOI: https://doi.org/10.1378/chest.126.3_suppl.627S
  103. Мурашко А.В. Антикоагулянтная терапия при беременности. Трудный пациент. 2009;7(1–2):8.
  104. [Murashko AV. Anticoagulant therapy in pregnant women. Trudnyi patsient. 2009;7(1–2):8. (In Russ)]
  105. Chen Y, Wu XX, Tan JP, et al. Effects of low molecular weight heparin and heparin-binding epidermal growth factor on human trophoblast in first trimester. Fertil Steril. 2012;97(3):764–70. doi: 10.1016/j.fertnstert.2011.12.002. DOI: https://doi.org/10.1016/j.fertnstert.2011.12.002
  106. Rodger MA, Hague WM, Kingdom J, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014;384(9955):1673–83. doi: 10.1016/S0140-6736(14)60793-5. DOI: https://doi.org/10.1016/S0140-6736(14)60793-5
  107. Clark P, Walker ID, Langhorne P, et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood. 2010;115(21):4162–7. doi: 10.1182/blood-2010-01-267252. DOI: https://doi.org/10.1182/blood-2010-01-267252
  108. Visser J, Ulander VM, Helmerhorst FM, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia HABENOX*: A randomised multicentre trial. Thromb Haemost. 2011;105(2):295–301. doi: 10.1160/TH10-05-0334. DOI: https://doi.org/10.1160/TH10-05-0334
  109. De Jong PG, Quenby S, Bloemenkamp KW, et al. 3ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia – study protocol for a randomized controlled trial. Trials. 2015;16(1):208. doi: 10.1186/s13063-015-0719-9. DOI: https://doi.org/10.1186/s13063-015-0719-9
  110. Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103(10):3695–9. doi: 10.1182/blood-2003-12-4250. DOI: https://doi.org/10.1182/blood-2003-12-4250
  111. Badawy AM, Khiary M, Sherif LS, et al. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol. 2008;28(3):280–4. doi: 10.1080/01443610802042688. DOI: https://doi.org/10.1080/01443610802042688
  112. Brenner B, Hoffman R, Blumenfeld Z, et al. Gestational Outcome in Thrombophilic Women with Recurrent Pregnancy Loss Treated by Enoxaparin B. Thromb Haemost. 2000;83(5):693–7. DOI: https://doi.org/10.1055/s-0037-1613894
  113. Козлов А.А., Берковский А.Л., Качалова Н.Д. и др. Пособие для врачей-лаборантов по методам исследования плазменного гемостаза АЧТВ, протромбиновый комплекс, тромбиновое время, фибриноген. М.: РАМН ГНЦ НПО «РЕНАМ», 2006. 20 с.
  114. [Kozlov AA, Berkovskii AL, Kachalova ND, et al. Posobie dlya vrachei-laborantov po metodam issledovaniya plazmennogo gemostaza AChTV, protrombinovyi kompleks, trombinovoe vremya, fibrinogen. (A manual for laboratory specialists for plasma hemostasis assessment: PTT, PCC, PT, fibrinogen.) Moscow: RAMN GNTs NPO «RENAM» Publ.; 2006. 20 p. (In Russ)]
  115. Kamal AH, Tefferi A, Pruthi RK. How to Interpret and Pursue an Abnormal Prothrombin Time, Activated Partial Thromboplastin Time, and Bleeding Time in Adults. Mayo Clin Proceed. 2007;82(7):864–73. doi: 10.4065/82.7.864. DOI: https://doi.org/10.4065/82.7.864
  116. Chitlur M. Challenges in the laboratory analyses of bleeding disorder. Thromb Res. 2012;130(1):1–6. doi: 10.1016/j.thromres.2012.03.011. DOI: https://doi.org/10.1016/j.thromres.2012.03.011
  117. Panteleev MA, Hemker HC. Global/integral assays in hemostasis diagnostics: promises, successes, problems and prospects. Thromb J. 2015;13(1):5. doi: 10.1186/s12959-014-0032-y. DOI: https://doi.org/10.1186/s12959-014-0032-y
  118. Goodacre S, Sampson FC, Sutton AJ, et al. Variation in the diagnostic performance of D-dimer for suspected deep vein thrombosis. Quart J Med. 2005;98(7):513–27. doi: 10.1093/qjmed/hci085. DOI: https://doi.org/10.1093/qjmed/hci085
  119. Riley RS, Gilbert AR, Dalton JB, et al. Widely Used Types and Clinical Applications of D-dimer Assay. Lab Med. 2016;47(2):90–102. doi: 10.1093/labmed/lmw001. DOI: https://doi.org/10.1093/labmed/lmw001
  120. Добровольский А.Б., Титаева Е.В. Коагулологические факторы риска тромбозов и лабораторный контроль антикоагулянтной терапии. Атеротромбоз. 2009;1(2):2.
  121. [Dobrovol’skii AB, Titaeva EV. Coagulologic risk factors for thrombosis and laboratory control of anticoagulant therapy. Aterotromboz. 2009;1(2):2. (In Russ)]
  122. Eichinger S. D-Dimer Testing in Pregnancy. Pathophys Haemost Thromb. 2005;33(5–6):327–9. doi: 10.1159/000083822. DOI: https://doi.org/10.1159/000083822
  123. Shainoff JR, Page IH. Significance of cryoprofibrin in fibrinogen-fibrin conversion. J Exper Med. 1962;116 (5):687. doi: 10.1084/jem.116.5.687. DOI: https://doi.org/10.1084/jem.116.5.687
  124. Onishi H, Kaniyu K, Iwashita M, et al. Fibrin monomer complex in normal pregnant women: a potential thrombotic marker in pregnancy. Ann Clin Biochem. 2007;44(Pt 5):449–54. doi: 10.1258/000456307781646076. DOI: https://doi.org/10.1258/000456307781646076
  125. Smith GF, Bang NU. Formation of Soluble Fibrin Polymers. Fibrinogen Degradation Fragments D and E Fail to Form Soluble Complexes with Fibrin Monomer. Biochemistry. 1972;11(16):2958–66. DOI: https://doi.org/10.1021/bi00766a006
  126. Ворошилина Е.С., Овсепян Р.А., Плотко Е.Э. и др. Диапазоны нормальных значений для параметров стандартных коагулологических тестов и теста тромбодинамики при физиологической беременности на разных сроках гестации. Вестник РГМУ. 2015;4:40–4.
  127. [Voroshilina ES, Ovsepyan RA, Plotko EE, et al. Reference ranges for standard coagulation tests and thrombodynamics assay during normal pregnancy at various gestation time. Vestnik RGMU. 2015;4:40–4. (In Russ)]
  128. Баландина А.Н., Сошитова Н.П., Полетаев А.А. и др. Тромбодинамика — метод интегральной оценки состояния системы гемостаза. Гематология и трансфузиология. 2012;57(приложение):95.
  129. [Balandina AN, Soshitova NP, Poletaev AA, et al. Thrombodynamics as a method of complex homeostasis assessment. Gematologiya i transfuziologiya. 2012;57(Suppl):95. (In Russ)]
  130. Атауллаханов Ф.И., Баландина А.Н., Варданян Д.М. и др. Применение теста тромбодинамики для оценки состояния системы гемостаза. Учебно-методическое издание. М.: Первый Московский государственный медицинский университет им. И.М. Сеченова, 2015. 72 с.
  131. [Ataullakhanov FI, Balandina AN, Vardanyan DM, et al. Primenenie testa trombodinamiki dlya otsenki sostoyaniya sistemy gemostaza. Uchebno-metodicheskoe izdanie. (Thrombodynamics test for the homeostatsis assessment: a manual). Moscow: IM Sechenov First Moscow State Medical University Publ.; 2015. 72 p. (In Russ)]
  132. Soshitova N, Lobastov K, Dementieva G, et al. The pilot evaluation of Thrombodynamics test capability in the assessment of LMWH individual effects and the prediction of postoperative DVT in patients with colon cancer. 59th Annual Meeting of the German, Austrian and Swiss Society of Thrombosis and Hemostasis Research (GTH), 2015. Dusseldorf, 2015.
  133. Урнова Е.С., Покровская О.С., Грачева М.А. и др. Гиперкоагуляционный синдром при множественной миеломе. Терапевтический архив. 2014;86(7):73–9. [Urnova ES, Pokrovskaya OS, Gracheva MA, et al. Hypercoagulability in multiple myeloma. Terapevticheskii arkhiv. 2014;86(7):73–9. (In Russ)]
  134. Belikov E, Litinskaya O, Davtyan K, et al. Efficiency of thrombodynamics for analysis of hemostasis in case of transitory ischemic attack after radio-frequency ablation in a patient with paroxysmal atrial fibrillation Running Head: Thrombodynamics in patient with AF. 59th Annual Meeting of the German, Austrian and Swiss Society of Thrombosis and Hemostasis Research (GTH) 2015. Dusseldorf, 2015.

Keywords:

thrombophilia, pregnancy, thrombodynamics

License

Copyright (c) 2017 Clinical Oncohematology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

  • Andrei Vladimirovich Gubkin, PhD, NA Semashko Central Clinical Hospital No. 2, 2 Budaiskaya str., Moscow, Russian Federation, 129128, Центральная клиническая больница № 2 им. Н.А. Семашко ОАО «РЖД», ул. Будайская, д. 2, Москва, Российская Федерация, 129128, e-mail: gubkinav@gmail.com
2017-3

Downloads

Published

01.07.2017

Issue

Vol. 10 No. 3 (2017)
HEMOSTASIS

How to Cite

Galaiko M.V., Rybina O.V., Litvinenko M.S., Klimov Y.V., Al’tshuler B.Y., Gubkin A.V. Thrombophilia and Pregnancy. Clinical Oncohematology. Basic Research and Clinical Practice. 2017;10(3):409–422. doi:10.21320/2500-2139-2017-10-3-409-422.